首页> 美国卫生研究院文献>Pediatric Rheumatology Online Journal >Rituximab resistant evans syndrome and autoimmunity in Schimke immuno-osseous dysplasia
【2h】

Rituximab resistant evans syndrome and autoimmunity in Schimke immuno-osseous dysplasia

机译:利妥昔单抗耐药埃文斯综合征和Schimke免疫性骨发育不良的自身免疫

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Autoimmunity is often observed among individuals with primary immune deficiencies; however, the frequency and role of autoimmunity in Schimke immuno-osseous dysplasia (SIOD) has not been fully assessed. SIOD, which is caused by mutations of SMARCAL1, is a rare autosomal recessive disease with its prominent features being skeletal dysplasia, T cell deficiency, and renal failure. We present a child with severe SIOD who developed rituximab resistant Evans syndrome (ES). Consistent with observations in several other immunodeficiency disorders, a review of SIOD patients showed that approximately a fifth of SIOD patients have some features of autoimmune disease. To our best knowledge this case represents the first patient with SIOD and rituximab resistant ES and the first study of autoimmune disease in SIOD.
机译:在具有原发性免疫缺陷的个体中经常观察到自身免疫。然而,尚未完全评估自身免疫在Schimke免疫性骨发育不良(SIOD)中的频率和作用。 SIOD是由SMARCAL1突变引起的,是一种罕见的常染色体隐性遗传疾病,其突出特征是骨骼发育异常,T细胞缺乏和肾功能衰竭。我们介绍了一名严重SIOD的儿童,该儿童发展了利妥昔单抗耐药性Evans综合征(ES)。与在其他几种免疫缺陷疾病中的观察结果一致,对SIOD患者的评论显示,大约五分之一的SIOD患者具有自身免疫性疾病的某些特征。据我们所知,该病例代表了首例具有SIOD和利妥昔单抗耐药性ES的患者,并且是SIOD中首例自身免疫性疾病的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号